Syros Pharmaceuticals (NASDAQ:SYRS) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of Syros Pharmaceuticals (NASDAQ:SYRS) in a report issued on Wednesday morning. The brokerage issued a sell rating on the stock.

Several other equities research analysts have also recently weighed in on SYRS. TD Cowen reaffirmed a “hold” rating on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. HC Wainwright reissued a “neutral” rating and set a $1.00 target price (down previously from $6.00) on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. JMP Securities reissued a “market perform” rating on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. Finally, Brookline Capital Management reissued a “hold” rating on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. One analyst has rated the stock with a sell rating, four have given a hold rating and one has issued a buy rating to the stock. Based on data from MarketBeat.com, Syros Pharmaceuticals currently has an average rating of “Hold” and a consensus price target of $3.33.

Syros Pharmaceuticals Stock Performance

Shares of SYRS opened at $0.09 on Wednesday. The company has a 50 day moving average price of $0.19 and a 200-day moving average price of $0.98. Syros Pharmaceuticals has a fifty-two week low of $0.07 and a fifty-two week high of $7.27. The stock has a market capitalization of $2.31 million, a PE ratio of -0.03 and a beta of 1.29.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. GSA Capital Partners LLP purchased a new position in shares of Syros Pharmaceuticals in the third quarter worth $34,000. Two Sigma Securities LLC purchased a new position in shares of Syros Pharmaceuticals in the fourth quarter worth $25,000. Finally, Exome Asset Management LLC raised its holdings in shares of Syros Pharmaceuticals by 87.6% in the third quarter. Exome Asset Management LLC now owns 298,575 shares of the company’s stock worth $642,000 after buying an additional 139,400 shares during the last quarter. Hedge funds and other institutional investors own 91.47% of the company’s stock.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.